Journal: Molecular Therapy. Nucleic Acids
Article Title: A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics
doi: 10.1016/j.omtn.2026.102936
Figure Lengend Snippet: A workflow of this study (A) Overview of the mechanism of action of N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) and the seven approved GalNAc-SiRNA drugs collected in this study. (B) Schematic structure of the developed computational model for a GalNAc-siRNA. (C) Schematic workflow of the model informed GalNAc-siRNA development powered by the established computational platform.
Article Snippet: Finally, the platform was utilized to support the development of an investigational new angiotensinogen ( AGT )-silencing GalNAc-siRNA, termed SAL0132 (developed by Shenzhen Salubris Pharmaceuticals Co., Ltd), from preclinic rats and monkey to clinical studies.
Techniques: Small Interfering RNA